Literature DB >> 7619995

Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer.

J Carratalá1, F Alcaide, A Fernández-Sevilla, X Corbella, J Lińares, F Gudiol.   

Abstract

We prospectively studied 260 episodes of bacteremia that occurred over a 6-year period in neutropenic patients with cancer. Twenty-three episodes were caused by viridans streptococci. Thirteen (57%) of these strains were penicillin-resistant (MICs of penicillin ranged from 0.25 micrograms/mL to 8 micrograms/mL). Ten of the 13 penicillin-resistant strains (77%) were highly resistant to penicillin (MIC, > or = 4 micrograms/mL). Rates of bacteremia due to highly penicillin-resistant viridans streptococci increased significantly from zero episodes per 1,000 admissions in 1987 to 17 episodes per 1,000 admissions in 1992 (P = .003). In a comparison between penicillin-resistant and penicillin-susceptible viridans streptococci bacteremia, the administration of beta-lactam antibiotics during the previous 2 weeks was the only factor significantly associated with penicillin-resistant cases: 9 (69%) of 13 patients with penicillin-resistant bacteremia had received beta-lactams vs. 2 (20%) of 10 patients with penicillin-susceptible bacteremia (P = .036). These findings may have significant clinical implications in the choice of both antimicrobial prophylaxis and empirical antibiotic regimens.

Entities:  

Mesh:

Year:  1995        PMID: 7619995     DOI: 10.1093/clinids/20.5.1169

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  27 in total

1.  PCR-Based methods for genotyping viridans group streptococci.

Authors:  S Alam; S R Brailsford; R A Whiley; D Beighton
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

2.  In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada.

Authors:  J C de Azavedo; L Trpeski; S Pong-Porter; S Matsumura; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

3.  Evaluation of the PASCO strep plus broth microdilution antimicrobial susceptibility panels for testing Streptococcus pneumoniae and other Streptococcal species.

Authors:  M J Mohammed; F C Tenover
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

4.  Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000.

Authors:  Andrea S Gershon; Joyce C S de Azavedo; Allison McGeer; Krystyna I Ostrowska; Deirdre Church; Daryl J Hoban; Godfrey K M Harding; Karl Weiss; Lewis Abbott; Fiona Smaill; Marie Gourdeau; Gilles Murray; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

5.  All detectable high-molecular-mass penicillin-binding proteins are modified in a high-level beta-lactam-resistant clinical isolate of Streptococcus mitis.

Authors:  A Amoroso; D Demares; M Mollerach; G Gutkind; J Coyette
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

6.  Viridans group streptococci bloodstream infections in neutropenic adult patients with hematologic malignancy: Single center experience.

Authors:  J Radocha; P Paterová; A Zavřelová; B Víšek; F Gabalec; H Žemličková; P Žák
Journal:  Folia Microbiol (Praha)       Date:  2017-08-03       Impact factor: 2.099

7.  Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae.

Authors:  Luz Balsalobre; María José Ferrándiz; Josefina Liñares; Fe Tubau; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

8.  Nationwide German multicenter study on the prevalence of antibiotic resistance in streptococcal blood isolates from neutropenic patients and comparative in vitro activities of quinupristin-dalfopristin and eight other antimicrobials.

Authors:  R R Reinert; C von Eiff; M Kresken; J Brauers; D Hafner; A Al-Lahham; H Schorn; R Lütticken; G Peters
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

9.  E test versus agar dilution for antimicrobial susceptibility testing of viridans group streptococci.

Authors:  S J Rosser; M J Alfa; S Hoban; J Kennedy; G K Harding
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

10.  Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci.

Authors:  I González; M Georgiou; F Alcaide; D Balas; J Liñares; A G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.